DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, will participate at the XXXV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), Europe’s leading organization for cataract and refractive surgeons, to be held in Lisbon, Portugal on October 7th through 11th.
The Presbia Flexivue Microlens is currently approved for sale in 42 countries around the world. The company is planning to make its final submission to the FDA before the end of 2017 in anticipation of approval in 2018. Several surgeons who have implanted the Presbia Flexivue Microlens commercially and as part of the FDA study will be sharing their hands-on experience with the product at ESCRS.
Prof. Tae Young Chung, who is conducting a clinical study with the Presbia Flexivue Microlens at Samsung Medical Center in South Korea, will present at the ESCRS congress.
Prof. Pallikaris, who has experience with the Presbia Flexivue Microlens since 2007, is participating in an Instructional Course titled “Corneal Inlay Technologies for the Treatment of Presbyopia”.
On October 5th, Dr. Fantozzi, who first performed the Presbia Flexivue Microlens procedure over seven years ago, will present long-term results at the Presbymania event, an event where experts from around the world gather to discuss the surgical treatment of presbyopia.
Dr. Karl Stonecipher, a clinical investigator who is participating in the FDA pivotal study of the Presbia Flexivue Microlens, will also conduct a presentation at the International Society of Presbyopia (ISOP) that is being held at the Saba Lisboa Hotel on October 6th in Lisbon.
Mr. Todd Cooper, President and CEO of Presbia will give a presentation at the Ophthalmology Futures European Forum, focusing on the transformation of presbyopia correction with the Presbia Flexivue Microlens. This will take place on Thursday, October 5th at the Myriad Crystal Center, Lisbon, Portugal.
“Presbia’s presentations being held at ESCRS and at ISOP will increase industry leaders’ awareness of the positive results that have been consistently reported globally by surgeons and patients using our Microlens as the treatment for near-vision loss,” said Todd Cooper, President and CEO of Presbia. “Surgeons will have an opportunity for hands-on experience with our product at the Presbia booth, enabling them to experience our unique presbyopia solution.”
Presbia representatives will be available for one-on-one meetings at booth number P288 during the ESCRS.
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties, including, but not limited to, the factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Accordingly, you are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens commenced in 2014.